TABLE 1.
Major characteristics of studies included in the analysis
| Aortic stenosis undergoing replacement | HFpEF | Carpal tunnel syndrome | LVH/HCM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nitsche 11 et al* | Rosemblum 12 et al | Scully 13 et al | Total | Benanni Smires 14 et al | Gonzalez‐Lopez 15 et al | Total | Vianello 16 et al | Zegri‐Reiriz 17 et al | Total | Maurizi 18 et al** | Cariou 19 et al* | Total | |
| Scintigraphic bone tracer | |||||||||||||
| 99mTc‐DPD | 99mTc‐PYP | 99mTc‐DPD | 99mTc‐DPD | 99mTc‐DPD | 99mTc‐HMDP | 99mTc‐DPD | / | 99mTc‐HMDP | |||||
| Number of patients | |||||||||||||
| All | 191 | 204 | 200 | 595 | 49 | 120 | 169 | 53 | 101 | 154 | 343 | 114 | 457 |
| TTRwt‐CA | 15 | 27 | 26 | 68 | 9 | 16 | 25 | 2 | 2 | 4 | 17 | 26 | 43 |
| TTRv‐CA | 0 | / | / | / | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 5 | 16 |
| Other CA | 1 | 0 | 0 | 1 | 6 | 0 | 6 | 0 | 1 | 1 | 4 | 19 | 23 |
| TTR‐CA prevalence | 7.9% | 13.2% | 13.0% | 11.4% | 18.4% | 13.3% | 14.8% | 3.8% | 1.9% | 2.6% | 8.2% | 27.2% | 12.9% |
| Age, years (Mean/median) | |||||||||||||
| All | 82 (78–86) | 83 ± 7 | 85 ± 5 | 83 | 76 ± 8 | 82 ± 8 | 79 | 72 (42–95) | 69 (64–77) | 71 | 60 ± 13 | 65 ± 21 | 63 |
| TTR‐CA | 84 (81–89) | 86 ± 5 | 88 ± 5 | 86 | 80 ± 5 | 86 ± 6 | 83 | 79 ± 0.5 | 85.5 ± 0.7 | 82 | 77 ± 6 | 72 ± 12* | 75 |
| Male pts, n (%) | |||||||||||||
| All | 95 (49.7) | 133 (65.2) | 99 (49.5) | 327 (54.9) | 28 (57.1) | 49 (40.8) | 77 (45.6) | 53 (100.0) | 32 (31.6) | 85 (55.2) | 199 (58.0) | 84 (73.7) | 283 (61.9) |
| TTR‐CA | 10 (62.5) | 26 (96.3) | 16 (61.5) | 52 (76.5) | 9 (100.0) | 8 (50.0) | 17 (68.0) | 2 (100.0) | 0 (0.0) | 2 (50.0) | 15 (88.2) | /(80.0)* | /(84.1) |
| Hypertension, n (%) | |||||||||||||
| All | 167 (87.3) | 175 (85.7) | 154 (77) | 496 (83.4) | 34 (69.4) | 101 (84.1) | 135 (79.8) | 30 (56.6) | 65 (64.4) | 95 (61.7) | / | 69 (60.5) | / |
| TTR‐CA | 14 (87.5) | 25 (92.6) | 19 (73.1) | 58 (85.3) | 2 (22.2) | 14 (87.5) | 16 (64.0) | / | / | / | / | / (44.0)* | / |
| Diabetes, n (%) | |||||||||||||
| All | 50 (26.2) | / | 48 (24.0) | 98 (25.1) | 13 (26.5) | 45 (37.5) | 58 (34.3) | 6 (11.3) | 32 (31.6) | 38 (24.7) | / | 22 (19.3) | / |
| TTR‐CA | 5 (31.2) | / | 3 (11.5) | 8 (21.4) | 2 (22.2) | 4 (25.0) | 6 (24.0) | / | / | / | / | /(16.0)* | / |
| Atrial fibrillation, n (%) | |||||||||||||
| All | 72 (37.7) | 83 (40.7) | 74 (37.0) | 229 (38.5) | 33 (67.3) | 80 (66.7) | 113 (66.9) | 7 (13.2) | 7 (6.9) | 14 (9.1) | 75 (21.8) | 41 (35.9) | 116 (25.4) |
| TTR‐CA | 9 (56.3) | 10 (37.0) | 11 (42.3) | 30 (44.1) | 8 (88.8) | 13 (81.2) | 21 (84.0) | 1 (50.0) | 0 (0.0) | 1 (25.0) | 4 (23.5) | /(50.0)* | /(36.8) |
| Pacemaker, n (%) | |||||||||||||
| All | 25 (13.1) | / | 23 (11.5) | 48 (12.3) | 0 (0.0) | 19 (15.8) | 19 (11.2) | 2 (3.8) | 5 (4.9) | 7 (4.5) | 13 (3.8) | 25 (21.9) | 38 (8.3) |
| TTR‐CA | 5 (31.2) | / | 4 (15.3) | 9 (23.2) | 0 (0.0) | 7 (43.8) | 7 (28.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.8) | /(34.0)* | /(19.9) |
| NT‐proBNP, ng/L (Mean/median) | |||||||||||||
| All | 1917 (783–5893) | 2142 (1002–5712) | 1467 (640–3337) | 1842 | / | 3524 (1500–7500) | / | / | 150 (57–316) | / | / | / | / |
| TTR‐CA | 3634 (1241 –6323) | 3132 (1812–6138) | 3702 (1286–5626) | 3489 | 2868 ± 2822 | 6467 (2818–13146) | 4668 | / | 2045 ± 1701 | / | 7276 ± 6344 | 3278* | / |
Values are reported as mean ± SD or median and interquartile ranges according to the original study publication. For studies reporting BNP values, these were multiplied by 6 to obtain corresponding NT‐proBNP values.
*This study presented data aggregated for all CA cases (ATTRwt, ATTRv and other CA, including AL). However, the study by Nitsche et al 11 had only 1 of 16 case of non‐TTR‐CA, whereas the study by Cariou et al 19 had 19 of 50 cases of non‐TTR‐CA. Thus, for this study only percentages were presented and averaged.
**For this study, only data for ATTRwt‐CA are presented, given that this was the only condition screened with bone scintigraphy.
Tc‐DPD, 99mTc‐3,3‐diphosphono‐1,2‐propanodicarboxylic acid; 99mTc‐PYP, 99mTc‐pyrophosphate; 99mTc‐HMDP, 99mTc‐hydroxymethylene‐diphosphonate; HFpEF, heart failure with preserved ejection fraction; LVH, left ventricular hypertrophy; HCM, hypertrophic cardiomyopathy.